Abstract
Complement activation by immune complexes is well-known. In the course of autoimmune disease, acute and chronic complement activation is the primary inducer of inflammation and tissue damage. Polyconal, polyspecific intravenous immunoglobulin (IVIg) preparations are a therapy of choice in a variety of autoimmune and inflammatory diseases. This review describes mechanisms by which IgG reduces complement activation or interferes with the action of proinflammatory complement-derived proteins. The known interference of IVIg with the biological activity of complement-derived proinflammatory proteins does not affect the generation of these potentially dangerous products, but can limit their devastating effects. Therefore, we embarked on studies on IVIg’s potential to attenuate complement activation and thus to prevent further generation of such dangerous molecules. We present here a revised view of how the central event of complement activation—namely, complement amplification—operates on a molecular level and how IVIg, with its physiological autoantibodies directed against some complement proteins, is able to downregulate amplification of complement C3 activation. Finally, we summarize results of a study in which clinical effects of IVIg and attenuation of complement activation were assessed. We propose that the anti-inflammatory effect of IVIg in a wide range of autoimmune diseases might be explained, at least in part, by attenuation of complement amplification.
Similar content being viewed by others
References
Kazatchkine, M. D. and Kaveri, S. V. (2001), N Engl J Med 345, 747–755.
Sewell, W. A. and Jolles, S. (2002), Immunology 107, 387–393.
Dalakas, M. C. (1998), Neurology 51, S37-S45.
Dalakas, M. C. (2002), Neurology 59, S13-S21.
Stahl, G. L., Xu, Y., Hao, L., et al. (2003), Am J Pathol 162, 449–455.
Harboe, M., Ulvund, G., Vien, L., Fung, M., and Mollnes, T. E. (2004), Clin Exp Immunol 138, 439–446.
Pangburn, M. K. and Muller-Eberhard, H. J. (1980), J Exp Med 152, 1102–1114.
Pangburn, M. K. (1983), Fed Proc 42, 139–143.
Pangburn, M. K., Pangburn, K. L. W., Koistinen, V., Meri, S., and Sharma, A. K. (2000), J Immunol 164, 4742–4751.
Lutz, H. U. and Jelezarova, E. (2006), Mol Immunol 43, 2–12.
Jelezarova, E., Luginbuehl, A., and Lutz, H. U. (2003), J Biol Chem 278, 51,806–51,812.
Lutz, H. U., Stammler, P., Jelezarova, E., Nater, M., and Späth, P. J. (1996), Blood 88, 184–193.
Jelezarova, E., Vogt, A., and Lutz, H. U. (2000), Biochem J 349, 217–223.
Gadd, K. J. and Reid, K. B. M. (1981), Biochem J 195, 471–480.
Fries, L. F., Gaither, T. A., Hammer, C. H., and Frank, M. M. (1984), J Exp Med 160, 1640–1655.
Takata, Y., Tamura, N., and Fujita, T. (1984), J Immunol 132, 2531–2537.
Vidarte, L., Pastor, C., Mas, S., et al. (2001), J Biol Chem 276, 38,217–38,223.
Lutz, H. U., Stammler, P., and Fasler, S. (1993), J Biol Chem. 268, 17,418–17,426.
Schenkein, H. A. and Ruddy, S. (1981), J Immunol 126, 7–10.
Winkelstein, J. A. and Shin, H. S. (1974), J Immunol 112, 1635–1642.
Nelson, B. and Ruddy, S. (1979), J Immunol 122, 1994–1999.
Lutz, H. U., Nater, M., and Stammler, P. (1993), Immunology 80, 191–196.
Kulics, J., Rajnavölgyi, E., Füst, G., and Gergely, J. (1983), Mol Immunol 20, 805–810.
Jacobs, R. J. and Reichlin, M. (1983), J Immunol 130, 2775–2781.
Zhang, M. X., Cutler, J. E., Han, Y. M., and Kozel, T. R. (1998) Infect Immun 66, 6027–6029.
Basta, M., Van Goor, F., Luccioli, S., et al. (2003), Nat Med 9, 431–438.
Woolhiser, M. R., Brockow, K., and Metcalfe, D. D. (2004), Clin Immunol 110, 172–180.
Ward, P. A. (2004), Nat Rev Immunol 4, 133–142.
Basta, M., Kirshom, P., Frank, M. M., and Fries, L. F. (1989), J Clin Invest 84, 1974–1981.
Basta, M. and Dalakas, M. C. (1994), J Clin Invest 94, 1729–1735.
Basta, M., Illa, I., and Dalakas, M. C. (1996), J Neuroimmunol 71, 227–229.
Lutz, H. U., Stammler, P., Bianchi, V., et al. (2004), Blood 103, 465–472.
Lutz, H. U., Bussolino, F., Flepp, R., et al. (1987), Proc Natl Acad Sci USA 84, 7368–7372.
Lutz, H. U., Fasler, S., Stammler, P., Bussolino, F., and Arese, P. (1988), Blood Cells 14, 175–195.
Price, J. F., Williams, B. D., and Challacombe, S. J. (1975), Nature (London) 257, 146–147.
Jelezarova, E. and Lutz, H. U. (2005), Mol Immunol 42, 1393–1403.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lutz, H.U., Späth, P.J. Anti-inflammatory effect of intravenous immunoglobulin mediated through modulation of complement activation. Clinic Rev Allerg Immunol 29, 207–212 (2005). https://doi.org/10.1385/CRIAI:29:3:207
Issue Date:
DOI: https://doi.org/10.1385/CRIAI:29:3:207